Over the past three months, Mersana Therapeutics Inc. [MRSN] ended the trading day at $23.28 and exhibited a change of -10.12% with a 24 hour trading and reached upto the volume of 1.02M compared to its recorded trading volume of 1.02 million. MRSN generated a 1 year amount change with 550.75%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by 8.50% with an amount shift of 43.73% over the last month.
On 30, November 2020, Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer. According to news published on Yahoo Finance, Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Arvin Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective immediately. Dr. Yang succeeds Dirk Huebner, M.D., who has stepped down as Chief Medical Officer but will remain with the Company until January 15, 2021, to assist with a smooth transition.
Analyst Birdseye View:
The most recent analyst activity for Mersana Therapeutics Inc. [NASDAQ:MRSN] stock was on April 29, 2020, when it was Initiated with a Buy rating from BTIG Research, which also raised its 12-month price target on the stock to $14. Before that, on September 29, 2020, JP Morgan Recapitulated a Neutral rating and elevated its amount target to $20. On January 21, 2020, H.C. Wainwright Reiterated a Buy rating and boosted its price target on this stock from $7 to $12. On March 11, 2019, JP Morgan Downgrade an Underweight rating. On November 14, 2018, Leerink Partners Upgrade an Outperform rating. On May 08, 2018, Robert W. Baird Initiated an Outperform rating. On March 19, 2018, JP Morgan Downgrade a Neutral rating.
In the past 52 weeks of trading, this stock has oscillated between a low of $3.58 and a peak of $26.71. Right now, the middling Wall Street analyst 12-month amount mark is $28.00. At the most recent market close, shares of Mersana Therapeutics Inc. [NASDAQ:MRSN] were valued at $23.28. According to the average price forecast, investors can expect a potential return of 2.14%.
Mersana Therapeutics Inc. [NASDAQ:MRSN] most recently reported quarterly sales of 11.0 million, which represented growth of -98.70%. This publicly-traded organization’s revenue is $507,506 per employee, while its income is -$339,855 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -30.32, -64.76, -63.42 and -61.14 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 9.40 and the whole liability to whole assets at 7.56. It shows enduring liability to the whole principal at 5.96 and enduring liability to assets at 0.05 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 25.50 points at 1st support level, the second support level is making up to 25.09. But as of 1st resistance point, this stock is sitting at 26.35 and at 26.79 for 2nd resistance point.
Mersana Therapeutics Inc. [MRSN] reported its earnings at -$0.33 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.3/share signifying the difference of -0.03 and -10.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.33 calling estimates for -$0.3/share with the difference of -0.03 depicting the surprise of -10.00%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Mersana Therapeutics Inc. [NASDAQ:MRSN] is 13.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.15. Now if looking for a valuation of this stock’s amount to sales ratio it’s 5.92 and it’s amount to book ratio is 3.32.
The most recent insider trade was by Lowinger Timothy B, Chief Science & Tech. Officer, and it was the sale of 8203.0 shares on Nov 20. Lowinger Timothy B, the Chief Science & Tech. Officer, completed a sale of 4101.0 shares on Oct 21. On Oct 20, Lowinger Timothy B, Chief Science & Tech. Officer, completed a sale of 4102.0 shares.